col blocks we are bridge builder col blocks
COVID answers in Scientific Journals all over the world


57 Results       Page 1

 [1] 
Springer-Verlag: Molecular Diversity
  original article Date Title Authors   Max. 6 Authors
1 [GO] 2023―Nov―09 An efficient eco-friendly, simple, and green synthesis of some new spiro-N-(4-sulfamoyl-phenyl)-1,3,4-thiadiazole-2-carboxamide derivatives as potential inhibitors of SARS-CoV-2 proteases: drug-likeness, pharmacophore, molecular docking, and DFT exploration Ahmed M. El-Saghier, Souhaila S. Enaili, Aly Abdou, Asmaa M. Kadry
2 [GO] 2023―Nov―07 An in-silico scaffold- hopping approach to design novel inhibitors against gp130: A potential therapeutic application in cancer and Covid-19 Alankar Roy, Ishani Paul, Shreya Luharuka, Sujay Ray
3 [GO] 2023―Jul―22 In-vitro antiviral activity and in-silico targeted study of quinoline-3-carboxylate derivatives against SARS-Cov-2 isolate Ravi Kumar Mittal, Priyank Purohit, Murugesan Sankaranarayanan, Mohammed Muzaffar-Ur-Rehman, Donatella Taramelli, Lucia Signorini, Maria Dolci, Nicoletta Basilico
4 [GO] 2023―Feb―24 Machine learning combines atomistic simulations to predict SARS-CoV-2 Mpro inhibitors from natural compounds Trung Hai Nguyen, Quynh Mai Thai, Minh Quan Pham, Pham Thi Hong Minh, Huong Thi Thu Phung
5 [GO] 2022―Dec―22 Pharmacoinformatic approach to identify potential phytochemicals against SARS-CoV-2 spike receptor-binding domain in native and variants of concern Raj Kumar Chinnadurai, Saravanaraman Ponne, Loganathan Chitra, Rajender Kumar, Palvannan Thayumanavan, Balanehru Subramanian
6 [GO] 2022―Dec―01 Evaluation of action of steroid molecules on SARS-CoV-2 by inhibiting NSP-15, an endoribonuclease Anantha Krishnan Dhanabalan, Sriram Srinivasa Raghavan, Selvakumar Rajendran, Velavan Ramasamy, Shaik Abdul Azeez Abdul, Nandhagopal Narayanasamy, Gunasekaran Krishnasamy
7 [GO] 2022―Nov―18 Nanobody-peptide-conjugate (NPC) for passive immunotherapy against SARS-CoV-2 variants of concern (VoC): a prospective pan-coronavirus therapeutics Mamta Panda, Elora Kalita, Satyendra Singh, Ketan Kumar, Vijay Kumar Prajapati
8 [GO] 2022―Nov―10 2,4-Dihydroxycinnamic acid as spike ACE2 inhibitor and apigenin as RdRp inhibitor in Nimbamritadi Panchatiktam Kashayam against COVID-19: an in silico and in vitro approach Maneesha Murali, Bhagyalakshmi Nair, V. R. Vishnu, T. P. Aneesh, Lekshmi R. Nath
9 [GO] 2022―Sep―03 Retraction Note: CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy Amgad M. Rabie
10 [GO] 2022―Aug―29 Correction to: Setomimycin as a potential molecule for COVID-19 target: in silico approach and in vitro validation Ravi S. Manhas, Harshita Tiwari, Mateen Noor, Ajaz Ahmed, Jyoti Vishwakarma, Raja B. M. Tripathi, Ravishankar Ramachandran, Sreedhar Madishetti, Debaraj Mukherjee, Amit Nargotra, Asha Chaubey
11 [GO] 2022―Aug―18 Computational studies indicated the effectiveness of human metabolites against SARS-Cov-2 main protease Rajarshi Roy, Md Fulbabu Sk, Omprakash Tanwar, Parimal Kar
12 [GO] 2022―Jun―23 In silico drug repurposing for coronavirus (COVID-19): screening known HCV drugs against the SARS-CoV-2 spike protein bound to angiotensin-converting enzyme 2 (ACE2) (6M0J) Konstantinos G. Kalamatianos
13 [GO] 2022―Jun―12 Targeting SARS-CoV-2 non-structural protein 13 via helicase-inhibitor-repurposing and non-structural protein 16 through pharmacophore-based screening Md. Nazmus Samdani, Niaz Morshed, Rumman Reza, Muhammad Asaduzzaman, Abul Bashar Mir Md. Khademul Islam
14 [GO] 2022―May―31 Amentoflavone derivatives significantly act towards the main protease (3CLPRO/MPRO) of SARS-CoV-2: in silico admet profiling, molecular docking, molecular dynamics simulation, network pharmacology Dipta Dey, Rajib Hossain, Partha Biswas, Priyanka Paul, Md. Aminul Islam, Tanzila Ismail Ema, Bibhuti Kumar Gain, Mohammad Mehedi Hasan, Shabana Bibi, Muhammad Torequl Islam, Md. Ataur Rahman, Bonglee Kim
15 [GO] 2022―May―27 Setomimycin as a potential molecule for COVID-19 target: in silico approach and in vitro validation Ravi S. Manhas, Harshita Tiwari, Mateen Noor, Ajaz Ahmed, Jyoti Vishwakarma, Raja B. M. Tripathi, Ravishankar Ramachandran, Sreedhar Madishetti, Debaraj Mukherjee, Asha Chaubey, Amit Nargotra
16 [GO] 2022―May―04 Discovery of adapalene and dihydrotachysterol as antiviral agents for the Omicron variant of SARS-CoV-2 through computational drug repurposing Ozkan Fidan, Somdutt Mujwar, Mateusz Kciuk
17 [GO] 2022―Mar―08 Chemical composition and therapeutic mechanism of Xuanbai Chengqi Decoction in the treatment of COVID-19 by network pharmacology, molecular docking and molecular dynamic analysis Liming Fan, Shuai Feng, Ting Wang, Xinli Ding, Xinxin An, Zhen Wang, Kun Zhou, Minjuan Wang, Xifeng Zhai, Yang Li
18 [GO] 2022―Mar―03 Defective ORF8 dimerization in SARS-CoV-2 delta variant leads to a better adaptive immune response due to abrogation of ORF8-MHC1 interaction Armi M. Chaudhari, Indra Singh, Madhvi Joshi, Amrutlal Patel, Chaitanya Joshi
19 [GO] 2022―Feb―18 Computer simulations on oxidative stress-induced reactions in SARS-CoV-2 spike glycoprotein: a multi-scale approach Oscar Bertran, Didac Martí, Juan Torras, Pau Turon, Carlos Alemán
20 [GO] 2022―Feb―13 Probing marine brown macroalgal phlorotannins as antiviral candidate against SARS-CoV-2: molecular docking and dynamics simulation approach Sathaiah Gunaseelan, Malaisamy Arunkumar, Manikka Kubendran Aravind, Santhalingam Gayathri, Senthil Rajkeerthana, Verma Mohankumar, Balasubramaniem Ashokkumar, Perumal Varalakshmi
21 [GO] 2022―Feb―09 Computational prediction of the effect of mutations in the receptor-binding domain on the interaction between SARS-CoV-2 and human ACE2 Ismail Celik, Abbas Khan, Fenny Martha Dwivany, Dong-Qing Wei, Trina Ekawati Tallei
22 [GO] 2022―Jan―10 A new glimpse on the active site of SARS-CoV-2 3CLpro, coupled with drug repurposing study Jurica Novak, Vladimir A. Potemkin
23 [GO] 2022―Jan―09 Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2 Avinash Mishra, Anurag S. Rathore
24 [GO] 2022―Jan―07 Multi-scale mechanism of antiviral drug-alike phytoligands from Ayurveda in managing COVID-19 and associated metabolic comorbidities: insights from network pharmacology Neha Choudhary, Vikram Singh
25 [GO] 2021―Oct―13 Computational investigation of drug bank compounds against 3C-like protease (3CLpro) of SARS-CoV-2 using deep learning and molecular dynamics simulation Tushar Joshi, Priyanka Sharma, Shalini Mathpal, Tanuja Joshi, Priyanka Maiti, Mahesha Nand, Veena Pande, Subhash Chandra
26 [GO] 2021―Sep―30 Repurposing the antibacterial drugs for inhibition of SARS-CoV2-PLpro using molecular docking, MD simulation and binding energy calculation Rohit Patel, Jignesh Prajapati, Priyashi Rao, Rakesh M. Rawal, Meenu Saraf, Dweipayan Goswami
27 [GO] 2021―Sep―04 Structure-based virtual screening, in silico docking, ADME properties prediction and molecular dynamics studies for the identification of potential inhibitors against SARS-CoV-2 Mpro Anbuselvam Mohan, Nicole Rendine, Mohammed Kassim Sudheer Mohammed, Anbuselvam Jeeva, Hai-Feng Ji, Venkateswara Rao Talluri
28 [GO] 2021―Jul―09 Hemagglutinin-esterase cannot be considered as a candidate for designing drug against COVID-19 Milad Zandi, Saber Soltani
29 [GO] 2021―Jul―02 In silico analysis and identification of antiviral coumarin derivatives against 3-chymotrypsin-like main protease of the novel coronavirus SARS-CoV-2 Rahman Abdizadeh, Farzin Hadizadeh, Tooba Abdizadeh
30 [GO] 2021―Jun―24 New insights into the catalytic mechanism of the SARS-CoV-2 main protease: an ONIOM QM/MM approach Henrique S. Fernandes, Sérgio F. Sousa, Nuno M. F. S. A. Cerqueira
31 [GO] 2021―Jun―12 Potential phytochemical inhibitors of SARS-CoV-2 helicase Nsp13: a molecular docking and dynamic simulation study R. P. Vivek-Ananth, Sankaran Krishnaswamy, Areejit Samal
32 [GO] 2021―Jun―09 Investigating the active compounds and mechanism of HuaShi XuanFei formula for prevention and treatment of COVID-19 based on network pharmacology and molecular docking analysis Juan Wang, Wen Ge, Xin Peng, Lixia Yuan, Shuaibing He, Xuyan Fu
33 [GO] 2021―May―18 Meticulous assessment of natural compounds from NPASS database for identifying analogue of GRL0617, the only known inhibitor for SARS-CoV2 papain-like protease (PLpro) using rigorous computational workflow Paritosh Parmar, Priyashi Rao, Abhilasha Sharma, Arpit Shukla, Rakesh M. Rawal, Meenu Saraf, Baldev V. Patel, Dweipayan Goswami
34 [GO] 2021―May―07 Identification of phytocompounds from Houttuynia cordata Thunb. as potential inhibitors for SARS-CoV-2 replication proteins through GC-MS/LC-MS characterization, molecular docking and molecular dynamics simulation Sanjib Kumar Das, Saurov Mahanta, Bhaben Tanti, Hui Tag, Pallabi Kalita Hui
35 [GO] 2021―Apr―15 Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation Bhaskarjyoti Gogoi, Purvita Chowdhury, Nabajyoti Goswami, Neelutpal Gogoi, Tufan Naiya, Pankaj Chetia, Saurov Mahanta, Dipak Chetia, Bhaben Tanti, Probodh Borah, Pratap Jyoti Handique
36 [GO] 2021―Apr―12 Structure-based identification of SARS-CoV-2 main protease inhibitors from anti-viral specific chemical libraries: an exhaustive computational screening approach Shovonlal Bhowmick, Achintya Saha, Sameh Mohamed Osman, Fatmah Ali Alasmary, Tahani Mazyad Almutairi, Md Ataul Islam
37 [GO] 2021―Apr―06 Identifying structural-functional analogue of GRL0617, the only well-established inhibitor for papain-like protease (PLpro) of SARS-CoV2 from the pool of fungal metabolites using docking and molecular dynamics simulation Priyashi Rao, Rohit Patel, Arpit Shukla, Paritosh Parmar, Rakesh M. Rawal, Meenu Saraf, Dweipayan Goswami
38 [GO] 2021―Mar―30 Pharmacoinformatics-based identification of transmembrane protease serine-2 inhibitors from Morus Alba as SARS-CoV-2 cell entry inhibitors Anshul Shakya, Rupesh V. Chikhale, Hans Raj Bhat, Fatmah Ali Alasmary, Tahani Mazyad Almutairi, Surajit Kumar Ghosh, Hassna Mohammed Alhajri, Siham A. Alissa, Shuchi Nagar, Md Ataul Islam
39 [GO] 2021―Mar―25 In silico evaluation of potential inhibitory activity of remdesivir, favipiravir, ribavirin and galidesivir active forms on SARS-CoV-2 RNA polymerase Ismail Celik, Meryem Erol, Zekeriya Duzgun
40 [GO] 2021―Mar―06 Exploring naphthyl derivatives as SARS-CoV papain-like protease (PLpro) inhibitors and its implications in COVID-19 drug discovery Sk. Abdul Amin, Kalyan Ghosh, Samayaditya Singh, Insaf Ahmed Qureshi, Tarun Jha, Shovanlal Gayen
41 [GO] 2021―Feb―14 Molecular docking, binding mode analysis, molecular dynamics, and prediction of ADMET/toxicity properties of selective potential antiviral agents against SARS-CoV-2 main protease: an effort toward drug repurposing to combat COVID-19 Himanshu Rai, Atanu Barik, Yash Pal Singh, Akhil Suresh, Lovejit Singh, Gourav Singh, Usha Yogendra Nayak, Vikash Kumar Dubey, Gyan Modi
42 [GO] 2021―Jan―25 Computational assessment of saikosaponins as adjuvant treatment for COVID-19: molecular docking, dynamics, and network pharmacology analysis Rupesh Chikhale, Saurabh K. Sinha, Manish Wanjari, Nilambari S. Gurav, Muniappan Ayyanar, Satyendra Prasad, Pukar Khanal, Yadu Nandan Dey, Rajesh B. Patil, Shailendra S. Gurav
43 [GO] 2021―Jan―05 First structure-activity relationship analysis of SARS-CoV-2 virus main protease (Mpro) inhibitors: an endeavor on COVID-19 drug discovery Sk. Abdul Amin, Suvankar Banerjee, Samayaditya Singh, Insaf Ahmed Qureshi, Shovanlal Gayen, Tarun Jha
44 [GO] 2021―Jan―05 COVID-19: inflammatory responses, structure-based drug design and potential therapeutics Neetu Tripathi, Neeraj Tripathi, Manoj Kumar Goshisht
45 [GO] 2021―Jan―04 Identification of novel inhibitors of angiotensin-converting enzyme 2 (ACE-2) receptor from Urtica dioica to combat coronavirus disease 2019 (COVID-19) Shobha Upreti, Jyoti Sankar Prusty, Satish Chandra Pandey, Awanish Kumar, Mukesh Samant
46 [GO] 2021―Jan―04 Curse of La Corona: unravelling the scientific and psychological conundrums of the 21st century pandemic Arpit Shukla, Paritosh Parmar, Gitanjali Kapoor, Dweipayan Goswami, Chaitanya Kumar Jha, Baldev Patel, Meenu Saraf
47 [GO] 2021―Jan―03 CoViTris2020 and ChloViD2020: a striking new hope in COVID-19 therapy Amgad M. Rabie
48 [GO] 2021―Jan―03 The anti-HCV, Sofosbuvir, versus the anti-EBOV Remdesivir against SARS-CoV-2 RNA dependent RNA polymerase in silico Abdo A. Elfiky, Eman B. Azzam, Medhat W. Shafaa
49 [GO] 2021―Jan―02 Designing of peptide aptamer targeting the receptor-binding domain of spike protein of SARS-CoV-2: an in silico study Arpita Devi, Nyshadham S. N. Chaitanya
50 [GO] 2020―Nov―25 Computational guided identification of a citrus flavonoid as potential inhibitor of SARS-CoV-2 main protease Neelutpal Gogoi, Purvita Chowdhury, Ashis Kumar Goswami, Aparoop Das, Dipak Chetia, Bhaskarjyoti Gogoi
51 [GO] 2020―Nov―17 Molecular docking studies, molecular dynamics and ADME/tox reveal therapeutic potentials of STOCK1N-69160 against papain-like protease of SARS-CoV-2 Olusola Olalekan Elekofehinti, Opeyemi Iwaloye, Sunday Solomon Josiah, Akeem Olalekan Lawal, Moses Orimoloye Akinjiyan, Esther Opeyemi Ariyo
52 [GO] 2020―Oct―20 Using Chou’s 5-steps rule to study pharmacophore-based virtual screening of SARS-CoV-2 Mpro inhibitors Hemlata Pundir, Tanuja Joshi, Tushar Joshi, Priyanka Sharma, Shalini Mathpal, Subhash Chandra, Sushma Tamta
53 [GO] 2020―Sep―30 A multimodal deep learning-based drug repurposing approach for treatment of COVID-19 Seyed Aghil Hooshmand, Mohadeseh Zarei Ghobadi, Seyyed Emad Hooshmand, Sadegh Azimzadeh Jamalkandi, Seyed Mehdi Alavi, Ali Masoudi-Nejad
54 [GO] 2020―Sep―29 Identification of potential inhibitors of coronavirus hemagglutinin-esterase using molecular docking, molecular dynamics simulation and binding free energy calculation Chirag N. Patel, Sivakumar Prasanth Kumar, Himanshu A. Pandya, Rakesh M. Rawal
55 [GO] 2020―Sep―02 Therapeutics for COVID-19: from computation to practices-where we are, where we are heading to Probir Kumar Ojha, Supratik Kar, Jillella Gopala Krishna, Kunal Roy, Jerzy Leszczynski
56 [GO] 2020―Jul―31 Identification of potential Mpro inhibitors for the treatment of COVID-19 by using systematic virtual screening approach Ashish M. Kanhed, Dushyant V. Patel, Divya M. Teli, Nirav R. Patel, Mahesh T. Chhabria, Mange Ram Yadav
57 [GO] 2020―Jun―29 Structure-based screening of novel lichen compounds against SARS Coronavirus main protease (Mpro) as potentials inhibitors of COVID-19 Tanuja Joshi, Priyanka Sharma, Tushar Joshi, Hemlata Pundir, Shalini Mathpal, Subhash Chandra
 [1] 

57 Results       Page 1



[de][en]

Last change 2023―Oct―27 12:08:13 UTC

© Daten-Quadrat 2022       Done in 0.004 sec